Recent News

• 02.07.2025 - Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair
• 01.10.2025 - Matinas BioPharma Receives NYSE Noncompliance Notice
• 10.31.2024 - Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction
• 08.14.2024 - Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update

Recent Filings

• 02.07.2025 - 3 Initial statement of beneficial ownership of securities
• 02.07.2025 - 8-K Current report
• 02.07.2025 - EX-99.1 EX-99.1
• 01.06.2025 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
• 11.13.2024 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.25.2024 - SC 13G Statement of Beneficial Ownership by Certain Investors